B. Wagner

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

David K Howse, A. Verier, M. Valis, 2018, Multiple sclerosis and related disorders.

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes

W. Haverkamp, T. Ziemssen, R. Dechend, 2020, Frontiers in Neurology.

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

W. Haverkamp, T. Ziemssen, R. Dechend, 2017, BMC Neurology.

Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease

E. Celius, S. Richter, B. Wagner, 2019, Journal of Neurology.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.